Ofev® (nintedanib) – New orphan indication
September 6, 2019 - The FDA announced the approval of Boehringer Ingelheim’s Ofev (nintedanib), to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Download PDF
